# Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

> **NCT07481032** · NA · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 1034 (estimated)

## Conditions studied

- Cirrhosis, Liver
- Hepatocellular Carcinoma (HCC)
- HEPATITIS B CHRONIC

## Interventions

- **DRUG:** Biejia-Ruangan compound
- **DRUG:** Biejia-Ruangan compound simulant

## Key facts

- **NCT ID:** NCT07481032
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-11-30
- **Target enrollment:** 1034 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481032, "Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07481032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*